Our Products



Topical treatment of atopic dermatitis (eczema).

JW-100 cleared or reduced eczema symptoms following 2 weeks of use. Results suggest that JW-100 may potentially prove superior to existing prescription drugs.

A Phase 3, double-blind, placebo-controlled multi-center trial is underway to evaluate the superiority of JW-100 to Eucrisa (an FDA-approved topical drug) in mild-to-moderate eczema.

Sales Channels
JW-100 is pre-revenue.

Next Steps
Market analysis and go-to-market plans are being developed with an anticipated product launch in 2023.

Investor Alerts

Get our news

For up-to-date company news delivered straight to your inbox or phone, sign up for Investor Alerts today.

To receive alerts via text message, send JUPW to
 +1 (844) 819-8138